Navigation Links
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Date:4/26/2009

icals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our annual and interim reports filed with the Frankfurt Stock Exchange. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include wi
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
4. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
7. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
8. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
9. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  Regulatory affairs professionals work at the interface ... strict and legislation is ever-changing. The continually evolving ... who have a deep understanding of government regulations, ... and demonstrate its use across various departments within ... Extension , in partnership with the University of ...
(Date:8/31/2015)... PARIS and MOUNTAIN VIEW, Calif. ... (NYSE: SNY ; EURONEXT: SAN) and the life ... collaborating to improve care and outcomes for people with ... leadership in diabetes treatments and devices with Google,s expertise ... The companies will explore how to improve diabetes care ...
(Date:8/31/2015)... , Aug. 31, 2015  AMRI (NASDAQ: ... a strategic collaboration focused on the development, manufacture ... pharmaceutical ingredients, ("APIs"). The collaboration combines Saneca,s strength ... expertise in developing and manufacturing controlled substance APIs ... tech transfer processes into these facilities. The collaboration ...
Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4
(Date:8/31/2015)... ... , ... The Bay Pines VA Healthcare System (VAHCS) remains focused ... more doctors and nurses and expanding existing facilities and services. Spine surgery will ... Anthony Jabre was selected to lead and grow the Bay Pines VAHCS’s new spine ...
(Date:8/31/2015)... (PRWEB) , ... September 01, 2015 , ... ... “ Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy ... medical breakthrough. Traumatic brain injury has been largely untreatable - with mostly palliative ...
(Date:8/31/2015)... ... 2015 , ... Since 1946, the doctors and staff at Clifton Dental Associates ... patient arrives at the office, the staff will make them feel welcome and comfortable. ... to create a complete dental treatment plan that is unique to each smile! ...
(Date:8/31/2015)... ... ... the FCPX LUT Soft pack from Pixel Film Studios, editors can quickly and easily add ... formula for modifying an image. The LUT changes every pixel's color to the corresponding color ... LUT Soft requires Final Cut Pro X 10.2 or newer. , By manipulating each ...
(Date:8/31/2015)... ... 31, 2015 , ... According to an article published August 3rd ... adolescents who underwent bariatric surgery “felt significantly better two years after surgery.” The article ... in the study felt that their “mental health had been normalized” at the point ...
Breaking Medicine News(10 mins):Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 2Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 3
... has negatively affected the treatment received by children and adolescents ... The meeting was hosted in association with the European Society ... hurdles faced by patients and those who care for them ... The Directive (2001/20/EC) has been one of the most ...
... 2012) The Scott & White Heart & Vascular Institute ... of Approval as a hospital performing Ventricular Assist Device ... permanent support for end stage heart failure by means ... the program demonstrated compliance with The Joint Commission,s national ...
... Gordon HealthDay Reporter , TUESDAY, Feb. 14 ... doesn,t speed recovery, new research shows. "We did ... diagnosis of acute sinusitis, and found no benefit from ... of acute sinusitis," said study author Dr. Jane Garbutt, ...
... , TUESDAY, Feb. 14 (HealthDay News) -- People who drank ... to 5 pounds over half a year, according to new ... divided into three groups: those who switched to water from ... those who weren,t advised to change beverages but were given ...
... , Blood tests have been a mainstay of diagnostic ... of information concerning health and disease. Nevertheless, blood derived ... fully mined for its vital health information, according to ... Institute. In a new study appearing in the ...
... in the field of Physical Anthropology. She not only ... Czech Republic, but she is also the Chair of ... the Department of Genetics, Physical Anthropology and Animal Physiology ... carried out numerous pieces of work into nutritional habits, ...
Cached Medicine News:Health News:Calls for policy changes as lives put at risk by bureaucracy 2Health News:Calls for policy changes as lives put at risk by bureaucracy 3Health News:Antibiotics Don't Help Most Sinus Infections, Study Finds 2Health News:Antibiotics Don't Help Most Sinus Infections, Study Finds 3Health News:Switching to Water, Diet Drinks Linked to Modest Weight Loss 2Health News:Following a trail of blood: A new diagnostic tool comes of age 2Health News:Following a trail of blood: A new diagnostic tool comes of age 3Health News:Analyzing the causes of obesity in the Romani ethnic group 2Health News:Analyzing the causes of obesity in the Romani ethnic group 3
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... X-Drape combines full 0.25 mm pb ... sterile drape material that can be ... between the clinician and the source ... clinician must be in very close ...
... The first mobile clinical assistant ... A convergence of technologies in the ... you normally do during your,shift such ... and take pictures using one single ...
Patent Pending lateral flow assay platform that contributes to increased sensitivty...
Medicine Products: